/PRNewswire/ Cordis today announced a strategic investment venture that will expand the scope of the global cardiovascular technology company into the.
Molecular Templates (NASDAQ:MTEM – Get Rating) had its price target cut by Barclays from $8.00 to $4.50 in a research note published on Wednesday morning, The Fly reports. They currently have an overweight rating on the biotechnology company’s stock. Separately, Zacks Investment Research upgraded shares of Molecular Templates from a sell rating to a hold […]
Wall Street analysts expect Molecular Templates, Inc. (NASDAQ:MTEM – Get Rating) to post $21.95 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Molecular Templates’ earnings, with the lowest sales estimate coming in at $5.00 million and the highest estimate coming in at $37.50 million. Molecular Templates […]
Focus On - Deals, Oncology, Bristol-Myers Squibb thepharmaletter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thepharmaletter.com Daily Mail and Mail on Sunday newspapers.